Vanguard Group Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has submitted a disclosure under Rule 8.3 of the Irish Takeover Panel Act, revealing its position in Avadel Pharmaceuticals plc. As of December 9, 2025, Vanguard holds 5,589,106 ordinary shares in Avadel, representing a 5.74% interest in the company. This disclosure follows dealings involving the purchase and sale of Avadel's US$0.01 ordinary shares.

Vanguard purchased 6,168 shares at a price of 21.31 USD per share and also sold 68 shares at the same price. The disclosure highlights that there are no cash-settled or stock-settled derivatives, nor any options or agreements to buy or sell more securities beyond what is reported.

No indemnity, option arrangement, or agreements influencing valuations or dealings have been entered by Vanguard, nor are there any understandings concerning voting rights or future acquisitions related to derivatives. Such transparency is crucial under the Irish Takeover Rules for interests exceeding 1%.